{"product_id":"lly-ansoff-analysis","title":"(LLY) Eli Lilly and Company ANSOFF Analysis Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDive Deeper Into the Growth Paths Behind the Analysis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Eli Lilly and Company Ansoff Matrix Analysis gives a concise, company-specific view of growth options across market penetration, market development, product development, and diversification—useful for strategy, investment, or planning. The page already includes a real preview\/sample of the analysis so you can check style and substance before buying; purchase the full version to receive the complete, ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Penetration\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiabetes franchise share defense\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEli Lilly and Company’s diabetes franchise spans 6 brands: Basaglar, Humalog, Humulin, Jardiance, Trajenta, and Trulicity. That mix covers basal, prandial, premixed, and type 2 care, which helps keep patients in Lilly-linked treatment cycles and raises prescriber stickiness. Multiple branded forms also make switching harder, so Lilly can defend share even as GLP-1 use and insulin competition rise.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOncology indication density\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEli Lilly and Company’s oncology base is broad: Alimta, Cyramza, Erbitux, Retevmo, Tyvyt, and Verzenio span lung, breast, colorectal, gastric, thyroid, and head-and-neck cancer. Verzenio is the anchor, with 2024 sales of $5.3 billion, and its label breadth supports repeat use across specialty oncology channels. That multi-indication density raises share of wallet and helps Lilly stay in the treatment pathway longer.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInflammation and immunology coverage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOlumiant and Taltz cover 5 key autoimmune uses: rheumatoid arthritis, psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. That 2-brand span lets Eli Lilly and Company compete across chronic, specialist-led care and widen its share of treatment starts. It also helps block switching, since prescribers can stay inside one familiar portfolio.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNeuroscience maintenance base\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEli Lilly and Company’s neuroscience base fits market penetration: Cymbalta, Emgality, and Zyprexa serve chronic, high-follow-up disorders like depression, neuropathic pain, migraine, schizophrenia, and bipolar disorder. This supports repeat prescribing in established markets; in 2025, Lilly reported $45.0 billion in revenue, reinforcing the scale behind this care model.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eChronic use drives steady refills.\u003c\/li\u003e\n\u003cli\u003eMultiple indications widen reuse.\u003c\/li\u003e\n\u003cli\u003eHigh continuity of care aids retention.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eAlliance-supported commercialization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEli Lilly and Company uses alliance-backed commercialization to push current products deeper into existing markets. Its ties with Incyte Corporation and Boehringer Ingelheim Pharmaceuticals, Inc. help widen payer access and distribution without changing the product mix. In 2024, Eli Lilly and Company reported $45.0 billion in revenue, showing how partner-led reach can support scale.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cp\u003eWider access, same products\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eAlliance sales can lift share fast\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eSupports payer and channel reach\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLilly’s Growth Comes From Winning the Same Patients Repeatedly\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMarket penetration at Eli Lilly and Company is built on depth in existing therapeutic areas, not new markets. In 2025, Company revenue was $45.0 billion, helped by repeat use in diabetes, oncology, immunology, and neuroscience. The play is simple: more indications, more refills, and tighter prescriber loyalty.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSignal\u003c\/th\u003e\n\u003cth\u003e2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e$45.0 billion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVerzenio sales\u003c\/td\u003e\n\u003ctd\u003e$5.3 billion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCore effect\u003c\/td\u003e\n\u003ctd\u003eRepeat prescribing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eAnalyzes Eli Lilly and Company’s growth strategy through the four core directions of the Ansoff Matrix\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a clear Eli Lilly Ansoff Matrix to quickly identify growth options and remove strategic planning guesswork.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eConsolidates primary, reputable Eli Lilly sources to quickly validate and trace Ansoff Matrix growth assumptions for defensible strategy and faster due diligence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eWorldwide diabetes rollout\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEli Lilly and Company can push its diabetes brands into new countries through its global sales network, which fits market development because the drugs are established and the geography expands. In 2025, Mounjaro and Zepbound helped drive total revenue above $45 billion, while Trulicity, Jardiance, and Humalog anchor diabetes access in many formularies. That gives Eli Lilly and Company a proven base to win launches in more national health systems.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational oncology expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEli Lilly and Company can push Alimta, Cyramza, Erbitux, Retevmo, and Verzenio into more countries because each maps to high-burden cancers like lung, breast, colorectal, gastric, and thyroid. Verzenio alone delivered $5.3 billion in 2024 sales, showing how specialty oncology access can scale fast once reimbursement and hospital pathways open. The model is simple: win local formularies, then convert diagnosed patients into repeat new-country revenue.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAutoimmune access beyond the core base\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOlumiant and Taltz can expand Lilly and Company beyond its core markets into more rheumatology and dermatology systems, since both drugs span several inflammatory uses and fit national treatment guidelines. Taltz delivered about $3.0 billion in 2024 sales, while Olumiant added about $1.0 billion, showing real demand outside the base. The Incyte collaboration also helps Olumiant reach wider markets faster.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNeuroscience market entry abroad\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEli Lilly and Company can push Cymbalta, Emgality, and Zyprexa into more countries because these are already known therapies for depression, migraine, and serious mental illness. Lilly’s 2025 revenue was about $45.0 billion, and WHO says depression affects 280 million people worldwide, so the demand base is real. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLower launch risk\u003c\/li\u003e\n\u003cli\u003eReuse trusted brands\u003c\/li\u003e\n\u003cli\u003eExpand across health systems\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThis makes neuroscience abroad a practical market development move, not a new-product bet.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePartner-enabled regional entry\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLilly’s partner-enabled regional entry uses 3 key alliances with Boehringer Ingelheim, Incyte, and Junshi Biosciences to reach markets beyond its U.S. base. This cuts local launch friction because partners bring regulatory know-how, country sales teams, and market access muscle where execution matters most.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e3 strategic regional partners\u003c\/li\u003e\n\u003cli\u003eFaster local commercialization\u003c\/li\u003e\n\u003cli\u003eBetter regulatory fit\u003c\/li\u003e\n\u003cli\u003eLower market-entry risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eFor Ansoff, this is market development: same science, new geographies. It matters most in complex markets where local evidence, pricing, and approvals can decide uptake.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEli Lilly’s Global Growth Play: Proven Drugs, Bigger Reach\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEli Lilly and Company’s market development case is built on taking proven drugs into more countries, not inventing new ones. In 2025, revenue topped $45 billion, and brands like Mounjaro, Zepbound, Verzenio, Taltz, and Olumiant already show strong demand that can scale across new health systems. Partner ties with Boehringer Ingelheim, Incyte, and Junshi Biosciences lower launch risk and speed local entry.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eDriver\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e2025 revenue\u003c\/td\u003e\n\u003ctd\u003e$45B+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVerzenio 2024 sales\u003c\/td\u003e\n\u003ctd\u003e$5.3B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTaltz 2024 sales\u003c\/td\u003e\n\u003ctd\u003e$3.0B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOlumiant 2024 sales\u003c\/td\u003e\n\u003ctd\u003e$1.0B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eEli Lilly and Company Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThis is the actual Ansoff Matrix analysis document you’ll receive upon purchase—no surprises, just professional quality.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eProduct Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInsulin formulation variants\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEli Lilly and Company’s Humalog and Humulin show product development through 8 insulin variants, including U-100, U-200, Mix 75\/25, Mix 50\/50, 70\/30, N, R, and U-500. These line extensions add new delivery choices to the same diabetes market, so patients and clinicians can match dose, speed, and mix needs more closely. That matters in a market where 38.4 million Americans live with diabetes.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVerzenio breast cancer expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVerzenio now spans HR+, HER2- metastatic, node-positive, and early breast cancer, so Lilly has turned one molecule into a wider breast-cancer franchise. In monarchE, adding Verzenio cut the risk of invasive disease recurrence by 32% at 5 years, and the drug delivered about $5.3 billion in 2024 sales. That is classic product development: new labeled uses in the same market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRetevmo precision oncology growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRetevmo adds a biomarker-led therapy to Eli Lilly and Company’s oncology line, targeting RET-altered metastatic NSCLC, medullary thyroid cancer, and other thyroid cancers. This is a new offering in established cancer markets, so it fits Ansoff product development. In 2025, it remained one of only a few RET-targeted options, helping Lilly sell into 3 precision-oncology settings with 1 medicine.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eEmgality headache expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEmgality moved from one neuroscience use to two: migraine prevention and episodic cluster headache in adults. That second approval widened the brand beyond migraine alone, so Lilly turned an existing asset into a new-use product inside the same market. For Ansoff, this is product development, not a new-market play, and it deepens the value of a 2-indication portfolio.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2 approved adult headache uses\u003c\/li\u003e\n\u003cli\u003eAdded cluster headache support\u003c\/li\u003e\n\u003cli\u003eSame neuroscience market\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCOVID-19 antibody launches\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEli Lilly and Company moved into COVID-19 antibodies with bamlanivimab plus etesevimab and later bebtelovimab, showing it could build and launch new biologics fast in infectious disease. Bamlanivimab and etesevimab received U.S. EUA in 2021, and bebtelovimab in 2022, adding a new line inside a huge treatment market.\u003c\/p\u003e\n\u003cp\u003eThis fit Ansoff product development: new products for an existing market. The launch also showed scale, with Lilly booking $45.0 billion in 2024 revenue, far above pre-pandemic levels, and using its biologics platform to move quickly as variants changed treatment demand.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNew biologics, same market\u003c\/li\u003e\n\u003cli\u003eFast FDA EUA path\u003c\/li\u003e\n\u003cli\u003eExpanded infectious-disease reach\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLilly Grows by Extending Winners, Not Chasing New Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEli Lilly and Company’s product development centers on new uses and line extensions, not new markets. Verzenio hit about $5.3B in 2024 sales, and Emgality now covers 2 adult headache uses; both show how Lilly widens value from one asset.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eProduct development\u003c\/th\u003e\n\u003cth\u003e2024-25 proof\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eVerzenio\u003c\/td\u003e\n\u003ctd\u003eNew breast-cancer labels\u003c\/td\u003e\n\u003ctd\u003e$5.3B sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEmgality\u003c\/td\u003e\n\u003ctd\u003e2 headache uses\u003c\/td\u003e\n\u003ctd\u003eCluster approval\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDiversification\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAbCellera antibody discovery\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLilly’s partnership with AbCellera Biologics gives it access to antibody discovery outside its legacy portfolio, which fits diversification in the Ansoff Matrix. AbCellera’s platform has helped Lilly move into new biologic programs and new therapeutic targets, not just sell more of the same drugs. That matters as Lilly pushed 2025 revenue above prior-year levels while widening its pipeline beyond core franchises.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLycia protein degradation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEli Lilly and Company’s Lycia Therapeutics deal is diversification because it adds targeted protein degradation, a different drug-making modality from Lilly’s current medicines. Lilly reported $45.0 billion in 2024 revenue and $10.7 billion in R\u0026amp;D spend, so this move uses that scale to widen the pipeline. It can open new markets in hard-to-treat diseases, not just existing therapy areas.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFoghorn chromatin biology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Foghorn Therapeutics partnership gives Eli Lilly and Company access to chromatin-regulating biology, a science base that is separate from its core commercial drugs. That makes it a clear diversification move in the Ansoff Matrix: Lilly is adding new biology and, over time, new therapy classes beyond diabetes and obesity. It also spreads pipeline risk across a platform with a different mechanism of action.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eEntos delivery science\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEli Lilly and Company’s collaboration with Entos Pharmaceuticals Inc. is a diversification move in the Ansoff Matrix, because new delivery science can create product forms Lilly does not already sell. Entos’ platform may help Lilly reach new tissues and improve dosing, widening the company beyond its current 2025 portfolio of diabetes, obesity, oncology, and immunology drugs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNew delivery tech = new product types\u003c\/li\u003e\n\u003cli\u003eExpands beyond current therapies\u003c\/li\u003e\n\u003cli\u003eSupports pipeline optionality\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eKumquat and Regor oncology programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePartnering with Kumquat Biosciences Inc. and Regor Therapeutics Group adds external oncology science to Eli Lilly and Company’s pipeline, so these are diversification moves, not line extensions. They can create new cancer assets in targets Lilly does not yet sell, which helps reach adjacent markets beyond today’s commercial base.\u003c\/p\u003e\n\u003cp\u003eWith cancer still a major global need, adding two outside platforms raises option value: more shots at first-in-class or best-in-class drugs, and less reliance on Lilly’s current portfolio. In Ansoff terms, this is product diversification through external innovation.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTwo external oncology bets\u003c\/li\u003e\n\u003cli\u003eNew assets, new targets\u003c\/li\u003e\n\u003cli\u003eExpands beyond current portfolio\u003c\/li\u003e\n\u003cli\u003eDiversification, not line extension\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLilly’s Big Bet on New Science Drives Diversification\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIn Eli Lilly and Company’s Ansoff Matrix, diversification shows up in deals like AbCellera, Lycia, and Foghorn, which add new biology, not just new sales from current drugs. Lilly’s 2025 revenue topped $45 billion, and its $10.7 billion 2024 R\u0026amp;D spend shows it can fund this wider risk. These bets aim at new markets in oncology, protein degradation, and novel delivery.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMove\u003c\/th\u003e\n\u003cth\u003eType\u003c\/th\u003e\n\u003cth\u003eWhy it fits\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAbCellera\u003c\/td\u003e\n\u003ctd\u003eDiversification\u003c\/td\u003e\n\u003ctd\u003eNew antibody discovery\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLycia\u003c\/td\u003e\n\u003ctd\u003eDiversification\u003c\/td\u003e\n\u003ctd\u003eNew drug modality\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57191849033993,"sku":"lly-ansoff-analysis","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/lly-ansoff-analysis.webp?v=1783678795","url":"https:\/\/dcfanalyst.com\/products\/lly-ansoff-analysis","provider":"DCF Analyst","version":"1.0","type":"link"}